Mon.Jan 08, 2024

article thumbnail

Advocacy Key For Supporting Transgender Rights in Health Care Settings

Drug Topics

Advocates can amplify the voices of transgender patients as they overcome barriers to health care, said Molly Crowther in a conversation at the 2023 Healthcare Advocate Summit.

198
198
article thumbnail

Pharmacy Focus: A Glimpse into Independent Prescribing

Pharmacy Times

Tune in to this episode of Pharmacy Focus for a deep dive into the world of independent pharmacists prescribing, featuring insights and expertise from Deeb Eid.

151
151
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Opinion: Americans are obsessed with health and fitness tracking. It’s time for a data diet

STAT

Turn on your TV or open a web browser this January, and you’ll be bombarded with ads for fitness trackers, smart scales, health apps, and other digital innovations promising to streamline your journey to a happier and healthier you. It’s the time of year when we’re most susceptible to such messaging: Surveys show that at least one-third of our New Year’s resolutions focus on exercising, losing weight, or eating better.

138
138
article thumbnail

Behind the Counter: Unveiling the Multifaceted Role of Pharmacists

Pharmacy Times

Pharmacists in community and retail practices are stepping out from behind the counter and becoming more involved in patient care.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

JPM: Four ways FDA is seeking to buoy gene therapy

pharmaphorum

Dr Peter Marks, director of the FDA Center for Biologics Evaluation and Research told a packed house in San Francisco for JPM that FDA wants to support gene therapies in 2024.

FDA 138
article thumbnail

JPM24: As cancer players jump head-first into ADC field, Novartis CEO explains how he's resisted the temptation

Fierce Pharma

San Francisco—Nearly all top cancer drugmakers have struck deals in the sizzling antibody-drug conjugate field—but not Novartis. | Nearly all top cancer drugmakers have struck deals in the sizzling antibody-drug conjugate field—but not Novartis. On Monday, the Swiss pharma’s CEO Vas Narasimhan explained how he's resisted the temptation.

135
135

More Trending

article thumbnail

JPM24: Bristol Myers Squibb CEO Boerner emphasizes organic pipeline over recent M&A deals

Fierce Pharma

It took Bristol Myers Squibb’s new CEO Chris Boerner 16 minutes into his 24-minute presentation to address the big news the company made last month, with its holiday

127
127
article thumbnail

Study: COVID-19 Vaccination Not to Blame for Worsening Migraines

Pharmacy Times

Stress may have more of an effect on migraines than COVID-19 infection or vaccination.

Vaccines 131
article thumbnail

JPM24: Merck expects $20B+ in post-Keytruda cancer sales thanks to Daiichi ADC deal, Moderna vaccine

Fierce Pharma

While some Merck & Co. investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.” | While some Merck & Co. investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.

Vaccines 126
article thumbnail

Study: If 66% of Adults 60 and Older Receive RSV Immunization, Infections Can Be Reduced

Pharmacy Times

If vaccination coverage was increased by 100%, outpatient care could be reduced by 81.2%, hospitalizations by 91.7%, and deaths by 91.3%.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

How Quantum Computing Will Impact Pharma in 2024: Q&A With Erik Huestis, Partner at Foley Hoag

PharmExec

Huestis discusses the ways that quantum simulation and quantum systems can be used in areas such as drug discovery and the creation and protection of intellectual property in the life sciences industry.

126
126
article thumbnail

A Cultural Framework Is Essential in Patient Care

Pharmacy Times

Recognizing that culture is a multifaceted concept can lead to more careful and thoughtful use of the term.

article thumbnail

Community-Level Social Determinants of Health Impact on Risk of Pregestational, Gestational Diabetes

Drug Topics

A study found that patients living in a food desert and in a less walkable neighborhood had an increased risk of gestational diabetes.

123
123
article thumbnail

Researchers Publish Recommendations on Low-Dose Computed Tomography Screenings for Lung Cancer

Pharmacy Times

The report allows management to provide guaranteed assessments throughout the screenings that could aid early detection, diagnosis, and lung cancer treatment.

121
121
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

JPM24: Johnson & Johnson CEO says Tecvayli, Talvey and several other meds are set to trounce analyst estimates

Fierce Pharma

Johnson & Johnson is starting the year with a new corporate identi | Despite all the recent changes at Johnson & Johnson, the company maintains an aggressive outlook for its pharmaceuticals division. In fact, J&J's sales forecasts for some drugs come in vastly higher than analyst numbers.

121
121
article thumbnail

STAT+: At JPM, biotech’s most prolific dealmaker sees a rosy 2024 for acquisitions

STAT

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years. That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech.

121
121
article thumbnail

JPM24: Mayo Clinic deepens AI commitment with new Cerebras Systems deal

Fierce Healthcare

SAN FRANCISCO — Real-world data and artificial intelligence are front and center among Mayo Clinic’s plans for the future. | The Minnesota nonprofit courted investors and other conference attendees Monday with details on its ongoing pilots and other AI initiatives.

article thumbnail

STAT+: CVS Health sees Medicare Advantage patients seek more care, eating into profits

STAT

Medicare Advantage members continue to go to the doctor and get health care procedures a lot more than predicted, CVS Health executives said at the J.P. Morgan Healthcare Conference on Monday. A persistent theme for health insurance companies throughout 2023 has been their Medicare Advantage members using more care than their actuaries projected, which has been eating into the profits they get from federally funded health care premiums.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Innovaccer joins AI scribe race, unveiling tool to simplify note-taking for doctors

Fierce Healthcare

Innovaccer, maker of digital tools for providers, has launched an AI assistant that transcribes, analyzes and summarizes conversations between providers and patients. | Sara Scribe prepares encounter notes and provides clinical insights into quality gaps, coding gaps and potential diagnoses for the clinician.

117
117
article thumbnail

STAT+: Sen. Sanders, others lawmakers open probe into asthma inhaler makers over pricing, patent maneuvers

STAT

Several U.S. lawmakers including Sen. Bernie Sanders (I-Vt.) are investigating the prices charged by four large drug companies for their asthma inhalers, arguing the devices unfairly cost Americans considerably more than what consumers pay in other countries. The lawmakers maintained that the companies — AstraZeneca , GSK , Teva Pharmaceutical , and Boehringer Ingelheim — charge between $200 and $600 in the U.S. for their inhalers, which are typically purchased monthly, but sell th

118
118
article thumbnail

Dollar General makes leadership change

Drug Store News

Steve Deckard will transition to executive vice president of store operations and development, succeeding Steve Sunderland who is leaving the company Jan. 19.

116
116
article thumbnail

This week in clinical trials: 2nd-5th January 2024

pharmaphorum

Stay up to date with the latest developments in clinical trials, including updates on Vicore, Mundipharma, Agios, Ultragenyx, EG 427, Orion, and MSD. Find out what these companies are working on and their potential impact on healthcare.

115
115
article thumbnail

STAT+: Mayo Clinic partners with supercomputing startup Cerebras to build custom AI tools

STAT

SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday. The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P.

article thumbnail

JPM24: Digital health funding hit $10.7B in 2023, the lowest in four years. How will the market shakeout?

Fierce Healthcare

SAN FRANCISCO — As many investors predicted, digital health funding took a dive in 2023 with startups bringing in $10.7 billion across 492 deals, representing the lowest amount of capital invested | Faced with tightening capital availability, startups got creative to stay afloat and looked for lifelines in 2023, according to Rock Health research analysts.

113
113
article thumbnail

Pharma firepower, M&A surge last year bode well for dealmaking prospects in 2024: EY

Fierce Pharma

Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. Morgan Healthcare Conference. | In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. The late surge of activity in 2023 also bodes well for a 2024 uptick, the group said.

112
112
article thumbnail

Wakefern opens call for Own Brands Snack summit

Drug Store News

Wakefern will host “CRAVECON ‘24” to source private label manufacturers of snacks and treats for expanding Bowl & Basket and Wholesome Pantry Store Brands.

Labelling 111
article thumbnail

AstraZeneca Vice President, Head of Breast Cancer Franchise, Discusses Impact of Truqap Approval

PharmExec

In an interview with Pharmaceutical Executive associate editor Don Tracy, Ashley Gaines, VP, head of breast cancer franchise, discusses newly approved Truqap.

111
111
article thumbnail

Isomorphic signs up Lilly, Novartis for $3bn AI drug hunt

pharmaphorum

Alphabet’s AI in drug discovery startup Isomorphic Labs signs collaborations with Eli Lilly and Novartis worth up to $3bn, its first two pharma partnerships

111
111
article thumbnail

STAT+: Hospitals try a new pitch to investors: other ways of making money

STAT

SAN FRANCISCO — If you learned anything about nonprofit hospitals on the first day of the J.P. Morgan Healthcare Conference, it’s that they’ve all but abandoned the prospect of making significant profit on patient care. Instead, they’re fully throwing their weight into other ways of making money — things like developing drugs or selling insurance.

Hospitals 111
article thumbnail

12 Questions with Marcus West

pharmaphorum

This 12 Questions With Marcus West explores the 60 Seconds remote coaching app founder's journey into corporate coaching and how West realised his clients would improve faster if they dedicated themselves to ongoing microlearning in between coaching sessions.

111
111
article thumbnail

JPM24: How Aetna charted a comeback in the 2024 MA star ratings

Fierce Healthcare

For the 2023 plan year, Aetna's performance in the annual Medicare Advantage star ratings took a massive hit, with just 21% of its members enrolled in plans that earned a score of four stars or mor | After a rough showing a year ago, Aetna bounced back for 2024, and was one of the stronger performers in the latest star ratings.

111
111
article thumbnail

Servier will apply ‘digital twin’ tech to Parkinson’s drug

pharmaphorum

Servier has added a third digital twin project to its collaboration with AI specialist Aitia, trying to identify Parkinson's patients who will respond to its LRRK2 inhibitor in clinical trials.

110
110
article thumbnail

STAT+: Backed by Mayo Clinic and Microsoft, a nonprofit forms to test AI tools used in health care

STAT

A group of academic hospitals and technology companies will form a new nonprofit venture to oversee a nationwide network of laboratories to test artificial intelligence tools designed for use in health care. The nonprofit will establish the laboratories at Mayo Clinic, Duke, Stanford, and other major universities and institutions around the country.